חוב כולל להון: G1 Pharma (GTHX)

G1 Therapeutics, Inc. (GTHX) specializes in developing bone marrow preservation agents for chemotherapy, ensuring stable demand regardless of market cycles. This chart illustrates the total debt-to-equity ratio, which stands at 2.08. Strong brand authority among oncologists drives loyalty, while stringent FDA requirements and patent protection create significant barriers to entry for new players.

The total debt-to-equity ratio isolates the fundamental stability of G1 Therapeutics, Inc. (GTHX) from market volatility by measuring the proportion of borrowed funds within the financing structure relative to equity. By analyzing the company's financial leverage dynamics, an investor assesses the default risk, which is critical for a company with a proprietary drug whose pricing power is limited by the slow adoption of the product into hospital formularies.